| Bioactivity | SBC-115076 is a potent proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PCSK9 is a proprotein convertase, which plays a crucial role in LDL receptor metabolism[1][2]. | ||||||||||||
| In Vivo | SBC-115076 (4 mg/kg; s.c.; daily for 3 weeks) reduces obesity and dyslipidemia, as well as improves insulin sensitivity in HFD-fed rats[1]. Animal Model: | ||||||||||||
| Name | SBC-115076 | ||||||||||||
| CAS | 489415-96-5 | ||||||||||||
| Formula | C31H33N3O5 | ||||||||||||
| Molar Mass | 527.61 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Chanisa Thonusin, et al. The comparative effects of high dose atorvastatin and proprotein convertase subtilisin/kexin type 9 inhibitor on the mitochondria of oxidative muscle fibers in obese-insulin resistant female rats. Toxicol Appl Pharmacol. 2019 Nov [2]. Wiciński M, et al. PCSK9 signaling pathways and their potential importance in clinical practice. EPMA J. 2017;8(4):391-402. Published 2017 Aug 14. |
SBC-115076
CAS: 489415-96-5 F: C31H33N3O5 W: 527.61
SBC-115076 is a potent proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PCSK9 is a proprotein convertase
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.